未知生产厂商
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular diseases. It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications. DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular diseases. It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.
DG041 is an antagonist of the EP3 receptor for prostaglandins E2 - a receptor involved in peripheral artery disease (PAD). DG041 produces concentration-dependent inhibition of one of the platelet activation pathways and reduces platelet aggregation without increasing bleeding time. Studies have shown that DG041 dramatically inhibits platelet activation mediated through VASP as well as platelet aggregation. DG041 also reduced levels of another indicator of platelet activation, p-selectin, and several markers of inflammation -- c-reactive protein (CRP), monocyte chemotactic protein 1 (MCP1), and soluble intracellular adhesion molecule (sICAM) -- in a dose-dependent manner.
Investigated for use/treatment in peripheral vascular disease.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
